38 results about "Acinus" patented technology

Previously we have identified a conserved domain (SAP, for SAF-A / B, Acinus, and PIAS) in the foot-and-mouth disease virus (FMDV) leader (L) protein coding region that is required for proper sub-cellular localization and function. Mutation of isoleucine 55 and leucine 58 to alanine (I55A, L58A) within the SAP domain resulted in a viable virus that displayed a mild attenuated phenotype in cell culture, along with altered sub-cellular distribution of L and failure to induce degradation of the transcription factor nuclear factor kappa-B. Here we report that inoculation of swine and cattle with this mutant virus results in the absence of clinical disease, the induction of a significant FMDV-specific neutralizing antibody response, and protection against subsequent homologous virus challenge. Remarkably, swine vaccinated with SAP mutant virus are protected against wild type virus challenge as early as two days post-vaccination suggesting that a strong innate as well as adaptive immunity is elicited. This variant could serve as the basis for construction of a live-attenuated FMD vaccine candidate.

The invention provides an amplification method of pancreatic cells. The amplification method comprises the following steps: sequentially carrying out digestion treatment, resuspension treatment, discontinuous density gradient centrifugation treatment and amplification treatment on pancreatic tissues. According to the amplification method disclosed by the invention, pancreatic ducts of mammals are used as sources of pancreatic precursor-like cells, and islet cells and acinar cells in obtained cell clusters are removed after the discontinuous density gradient centrifugal treatment, thus being good for improving the yield of pancreatic precursor-like cells, and avoiding ethical limitations and possible carcinogenic risk caused by the use of embryonic stem cells; and an amplification culture medium used in the invention comprises a reprogramming substance consisting of a plurality of small molecule compounds, so as to avoid the risks of nonspecificity, off-target deletion, etc., which are easily caused by changing gene sequences by using a gene editing method. The invention also provides a differentiation method and application of the pancreatic precursor-like cells obtained by the amplification method.

The invention discloses a feed additive of promoting mammary gland development of replacement gilts and gestating sows through a nutritional means. The feed additive is composed of the following components according to the following proportions: 15-30% of cysteamine hydrochloride, 10-30% of vitamin E, 5-25% of daidzein, and the balance being glucose. The additive can modulate neuroendocrine system of the sows, increase intake for mammary gland nutrients of the sows, stimulate growth of mammary gland lobular acinus and mammary gland ducts, promote mammary gland development of the replacement gilts and gestating sows, and lay a good foundation for milk output of lactating sows.

Provided herein are novel lipase inhibitors and methods of using them to treat inflammation, multisystem organ failure, necrotizing pancreatic acinar cell death, acute pancreatitis, sepsis (eg, culture-negative sepsis), burns, and acne. For example, provided herein are two novel lipase inhibitors for use in the methods described herein: (I) (II) or a pharmaceutically acceptable salt thereof.

The invention relates to the technical field of traditional Chinese medicine preparations, in particular to a medicine for treating mammary gland hyperplasia (known as breast addiction in traditional Chinese medicine), a preparation method and application thereof. The medicine is prepared from Ashitaba ethanol extract, malt water extract and hawthorn water extract. By comparing the treatment of model rats suffering from mammary gland hyperplasia, the compound medicine of the present invention can effectively: 1. reduce the serum estradiol content and increase the serum progesterone hormone level; The number of hyperplasia; ③ reduce the number of obliterated acini in the lobules of breast tissue; it has a good effect of soothing the liver and eliminating breast addiction.

The invention discloses a construction method of a pancreatic duct epithelial cell and pancreatic acinar cell co-culture system for simulating in vivo microenvironment, and belongs to the technical field of cell biology. The method comprises the steps of inoculating an upper layer of a Transwell dual-layer culturing chamber with original generation pancreatic acinar cells, inoculating a lower layer of the Transwell dual-layer culturing chamber with human pancreatic duct epithelial cells, performing co-culturing, adding sodium taurocholate in the pancreatic duct epithelial cells at the lower layer of the Transwell dual-layer culturing chamber, and observing the vitality, the shape and the apoptosis of the upper layer pancreatic acinar cells. Damage of the pancreatic duct epithelial cells and the pancreatic acinar cells are combined, a non-contact type co-culture manner is adopted for building the pancreatic duct epithelial cell and pancreatic acinar cell co-culture system. In the co-culture system, the two cells can exchange exocytosis secretion substances through Transwell transmembrane. The system can well simulate the pancreatitis induced by cholestasis, and the invention provides an in vitro cell model which can really reflect pancreatitis induced by cholestasis.

The invention provides a traditional Chinese medicine composition for treating hyperplasia of mammary glands. The traditional Chinese medicine composition is prepared from the following active ingredients in parts by weight: 1-5 parts of codonopsis pilosula, 3-8 parts of astragalus mongholicus, 1-5 parts of poria cocos, 1-5 parts of radix paeoniae alba, 1-5 parts of platycodon grandiflorum and 0.5-3 parts of liquorice. The traditional Chinese medicine composition can obviously reduce E2 and P levels in blood serum of a model rat, increases an E2 / P ratio, reduces nipple height of the model rat, relieves hyperemia and edema of a mammary tissue, reduces acinus number of lobules of the mammary glands, relieves epithelial proliferation of acinus, inhibits acinus secretion, improves the epithelial proliferation of a catheter, and has an effect of treating the hyperplasia of mammary glands. The invention further provides a method for preparing the traditional Chinese medicine composition.

The present invention relates to methods and pharmaceutical compositions useful for the treatment of hyperglycemia. Thorough multiple analyses, inventors demonstrated that Gfi1 is expressed in pancreatic acinar cells, starting from the first stages of pancreatic embryonic development. Furthermore, they observed that Gfi1 mRNA levels remain steady throughout embryonic development, while they significantly increase during the first days of life. They challenged conditional mutant mice with high fat diet for 5 months and monitored their weight and glycemia weekly. All the animals displayed a rapid increase in body mass as expected. While control mice rapidly developed a massive hyperglycemia, mutant mice remained normoglycemic throughout the entire experiment. A similar protection from induced diabetes was observed upon treatment with a high dose of Streptozotocin. Accordingly, the present invention relates to a method of treating hyperglycemia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an inhibitor of Gfi1.

The invention discloses the application of a flavonoid compound in snow chrysanthemum and its pharmaceutical composition in the preparation of medicine for treating acute pancreatitis. The invention provides an application of a flavonoid compound in the preparation of a medicine for treating acute pancreatitis. The flavonoids can significantly improve the necrosis of pancreatic acinar cells, and protect the local and systemic symptoms of two kinds of acute pancreatitis. The present invention will fill the medical value of snow chrysanthemum and the flavonoids isolated therein in the protection of pancreatitis, and provide new diagnosis and treatment methods and application prospects for clinical screening and / or preparation of drugs for the treatment of acute pancreatitis. a new choice.

The invention discloses the application of alpha-lactose for preparing health care foods capable of preventing and treating acute pancreatitis, and belongs to the field of health care foods. The alpha-lactose can reduce pancreatic tissue oedema, serum amylase, and the level of pancreatic tissue medulla peroxidase MPO so as to reduce an inflammatory reaction in an acute pancreatitis process; besides, the alpha-lactose can reduce inflammation mediators in pancreatic tissues and pancreatic acinar cells, such as an MCP-1 level and a TNF- alpha level. In addition, the alpha -lactose has the effect of restraining the activation of signal routes for regulating protein kinase (ERK1 / 2MAPK) and nuclear factors KB (NF-KB) protein outside cells, reduces the soaking of immunocyte, such as neutrophilic granulocyte and macrophage, in pancreatic tissues, has a notable protective effect on acute pancreatitis, and can be used for preparing health care foods capable of preventing and treating acute pancreatitis.